North America Colorectal Cancer Market to 2027 - Regional Analysis and Forecasts by Modality (Diagnosis Type, Therapy Type, Imaging Type); End User (Hospitals, Diagnostic and Research Laboratories), and Country

List of Tables

The colorectal cancer market in North America is expected to grow from US$ 8,559.27 million in 2022 to US$ 11,198.11 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.

Colorectal cancer is one of the most commonly found lethal cancers in individuals with the combined influence of genetic and environmental factors. A significant population in North America is diagnosed with colorectal cancer. According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, an estimated 1.93 million adults in the US were diagnosed with colon and rectum cancer, and 53,200 deaths were caused by colorectal cancer in 2020. These statistics showcase increased demand for advanced cancer diagnostics and therapeutics in the region. Thus, the rising prevalence of colorectal cancer and the rising number of patients diagnosed with the disease are driving the growth of the North America colorectal cancer market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America colorectal cancer market at a substantial CAGR during the forecast period.

North America Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

North America Colorectal Cancer Market Segmentation

The North America colorectal cancer market is segmented into modality, end user, and country. Based on modality, the North America colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period. Based on end user, the North America colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share. Based on country, the North America colorectal cancer market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2022.

Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies operating in the North America colorectal cancer market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America colorectal cancer market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America colorectal cancer market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the colorectal cancer market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Product Code: TIPRE00009241

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Colorectal Cancer Market - By Modality
- 1.3.2 North America Colorectal Cancer Market - By End User
- 1.3.3 North America Colorectal Cancer Market - By Country

2. North America Colorectal Cancer Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Colorectal Cancer- Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Expert Opinion

5. North America Colorectal Cancer Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Colorectal Cancer
- 5.1.2 New Product Launches
- 5.1.3 Benefits Offered by Generic Drugs
5.2 Market Restraints
- 5.2.1 Pricing Pressure on Drug Manufacturers
5.3 Future Trends
- 5.3.1 Inclination Toward Personalized Medicine
5.4 Impact Analysis

6. North America Colorectal Cancer Market- North America Analysis

6.1 North America Colorectal Cancer Market Revenue Forecast and Analysis
- 6.1.1 Overview

7. North America Colorectal Cancer Market Analysis - By Modality

7.1 Overview
7.2 North America Colorectal Cancer Market Revenue Share, By Modality 2022 & 2028 (%)
7.3 Diagnosis Type
- 7.3.1 Overview
- 7.3.2 Diagnosis Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.3 Immunohistochemistry
  - 7.3.3.1 Overview
  - 7.3.3.2 Immunohistochemistry: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.4 Stool Test
  - 7.3.4.1 Overview
  - 7.3.4.2 Stool Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.5 Flexible Sigmoidoscopy
  - 7.3.5.1 Overview
  - 7.3.5.2 Flexible Sigmoidoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.6 Colonoscopy
  - 7.3.6.1 Overview
  - 7.3.6.2 Colonoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.7 CEA Test
  - 7.3.7.1 Overview
  - 7.3.7.2 CEA Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.8 Other Test
  - 7.3.8.1 Overview
  - 7.3.8.2 Other Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Therapy Type
- 7.4.1 Overview
- 7.4.2 North America Therapy Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.3 Chemotherapy
  - 7.4.3.1 Overview
  - 7.4.3.2 Chemotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.3.3 Alkylating Agent
    - 7.4.3.3.2 Overview
    - 7.4.3.3.3 Alkylating Agent: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.3.4 Antimetabolites
    - 7.4.3.4.2 Antimetabolites: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.3.5 Others
    - 7.4.3.5.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.4 Immunotherapy
  - 7.4.4.1 Overview
  - 7.4.4.2 Immunotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.3 Panitumumab
    - 7.4.4.3.2 Overview
    - 7.4.4.3.3 Panitumumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.4 Cetuximab
    - 7.4.4.4.2 Overview
    - 7.4.4.4.3 Cetuximab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.5 Bevacizumab
    - 7.4.4.5.2 Overview
    - 7.4.4.5.3 Bevacizumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.6 Others
    - 7.4.4.6.2 Overview
    - 7.4.4.6.3 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.5 Chemoprotectant
  - 7.4.5.1 Overview
  - 7.4.5.2 Chemoprotectant: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.6 Others
  - 7.4.6.1 Overview
  - 7.4.6.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Imaging Type
- 7.5.1 Overview
- 7.5.2 North America Imaging Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5.3 Computed Tomography (CT)
  - 7.5.3.1 Overview
  - 7.5.3.2 Computed Tomography (CT): Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5.4 Magnetic Resonance Imaging (MRI)
  - 7.5.4.1 Overview
  - 7.5.4.2 Magnetic Resonance Imaging (MRI): Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5.5 Others
  - 7.5.5.1 Overview
  - 7.5.5.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Colorectal Cancer Market Revenue and Forecast To 2028 - By End User

8.1 Overview
8.2 North America Colorectal Cancer Market Revenue Share, By End User 2022 & 2028 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Diagnostic and Research Laboratories
- 8.4.1 Overview
- 8.4.2 Diagnostic and Research Laboratories: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Colorectal Cancer Market Revenue and Forecast to 2028 - Country Analysis

9.1 North America: Colorectal Cancer Market
- 9.1.1 Overview
- 9.1.2 North America: Colorectal Cancer Market, by Country, 2022 & 2028 (%)
  - 9.1.2.1 US: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.2.1.2 US: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
    - 9.1.2.1.3 US: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.2.1.3.1 US: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.2.1.3.2 US: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
    - 9.1.2.1.3.2.1 US: Colorectal Cancer Market, by Chemotherapy- 2019-2028 (US$ Million)
    - 9.1.2.1.3.2.2 US: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.2.1.3.3 US: Colorectal Cancer Market, by Imaging Type - 2019-2028 (US$ Million)
    - 9.1.2.1.4 US: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
  - 9.1.2.2 Canada: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.2.2.2 Canada: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
    - 9.1.2.2.3 Canada: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.2.2.3.1 Canada: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.2.2.3.1.1 Canada: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
    - 9.1.2.2.3.1.2 Canada: Colorectal Cancer Market, by Chemotherapy- 2019-2028 (US$ Million)
    - 9.1.2.2.3.2 Canada: Colorectal Cancer Market, by Imaging Type - 2019-2028 (US$ Million)
    - 9.1.2.2.4 Canada: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
  - 9.1.2.3 Mexico: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.2.3.2 Mexico: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
    - 9.1.2.3.3 Mexico: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.2.3.3.1 Mexico: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.2.3.3.2 Mexico: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
    - 9.1.2.3.3.2.1 Mexico: Colorectal Cancer Market, by Chemotherapy- 2019-2028 (US$ Million)
    - 9.1.2.3.3.2.2 Mexico: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.2.3.3.3 Mexico: Colorectal Cancer Market, by Imaging Type - 2019-2028 (US$ Million)
    - 9.1.2.3.4 Mexico: Colorectal Cancer Market - Revenue and Forecast To 2028, By End Users (US$ Million)

10. Colorectal Cancer Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies In The Colorectal Cancer Market, 2022-2028
10.3 Organic Developments
- 10.3.1 Overview
- 10.3.2 Organic Growth Strategies In The Colorectal Cancer Market, 2022-2028
10.4 Inorganic Developments
- 10.4.1 Overview
- 10.4.2 Inorganic Growth Strategies In The Colorectal Cancer Market, 2022-2028

11. Company Profiles

11.1 Epigenomics AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Clinical Genomics Technologies Pty. Ltd.
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Abbott
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Amgen Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 F. HOFFMANN-LA ROCHE LTD.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bruker Corporation
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Quest Diagnostics Incorporated
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Volitionrx Limited
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms